{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:21:39Z","timestamp":1793917299506,"version":"4.8.0"},"reference-count":220,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2022YFC3502101"],"award-info":[{"award-number":["2022YFC3502101"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2017ZX09304016"],"award-info":[{"award-number":["2017ZX09304016"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC 81970513"],"award-info":[{"award-number":["NSFC 81970513"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC 82270619"],"award-info":[{"award-number":["NSFC 82270619"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s12072-023-10633-7","type":"journal-article","created":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T18:02:06Z","timestamp":1708797726000},"page":"384-419","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2928-3425","authenticated-orcid":false,"given":"Yimin","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gongying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingmin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieting","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzheng","family":"Zhuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongtao","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dachuan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxian","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Technology Committee on DILI Prevention, Management, Chinese Medical Biotechnology Association; Study Group on Drug-Induced Liver Disease, Chinese Society of Hepatology, Chinese Medical Association","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,24]]},"reference":[{"key":"10633_CR1","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/liv.15262","volume":"42","author":"X Li","year":"2022","unstructured":"Li X, Tang J, Mao Y. Incidence and risk factors of drug-induced liver injury. Liver Int. 2022;42:1999\u20132014","journal-title":"Liver Int"},{"key":"10633_CR2","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1053\/jhep.2002.34857","volume":"36","author":"C Sgro","year":"2002","unstructured":"Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36:451\u2013455","journal-title":"Hepatology"},{"issue":"7","key":"10633_CR3","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","volume":"144","author":"ES Bj\u00f6rnsson","year":"2013","unstructured":"Bj\u00f6rnsson ES, Bergmann OM, Bj\u00f6rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419\u20131425","journal-title":"Gastroenterology"},{"key":"10633_CR4","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/j.1365-2036.2006.03117.x","volume":"24","author":"MB De Valle","year":"2006","unstructured":"De Valle MB, Av Klinteberg V, Alem N, Olsson R, Bj\u00f6rnsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther. 2006;24:1187\u20131195","journal-title":"Aliment Pharmacol Ther"},{"key":"10633_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","volume":"129","author":"RJ Andrade","year":"2005","unstructured":"Andrade RJ, Lucena MI, Fern\u00e1ndez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512\u2013521","journal-title":"Gastroenterology"},{"key":"10633_CR6","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40264-017-0547-9","volume":"40","author":"M Vega","year":"2017","unstructured":"Vega M, Verma M, Beswick D, et al. The incidence of drug- and herbal and dietary supplement-induced liver injury: preliminary findings from gastroenterologist-based surveillance in the population of the state of delaware. Drug Saf. 2017;40:783\u2013787","journal-title":"Drug Saf"},{"key":"10633_CR7","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/ajg.2012.138","volume":"107","author":"KT Suk","year":"2012","unstructured":"Suk KT, Kim DJ, Kim CH, et al. A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol. 2012;107:1380\u20131387","journal-title":"Am J Gastroenterol"},{"key":"10633_CR8","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1053\/j.gastro.2019.02.002","volume":"156","author":"T Shen","year":"2019","unstructured":"Shen T, Liu Y, Shang J, et al. Incidence and etiology of drug-induced liver injury in Mainland China. Gastroenterology. 2019;156:2230\u20132241","journal-title":"Gastroenterology"},{"key":"10633_CR9","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1572-0241.2006.01019.x","volume":"102","author":"R Vuppalanchi","year":"2007","unstructured":"Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol. 2007;102:558\u2013562","journal-title":"Am J Gastroenterol"},{"key":"10633_CR10","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.cgh.2018.08.016","volume":"17","author":"AC Breu","year":"2019","unstructured":"Breu AC, Patwardhan VR, Nayor J, et al. A multicenter study into causes of severe acute liver injury. Clin Gastroenterol Hepatol. 2019;17:1201\u20131203","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10633_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.alcohol.2016.07.001","volume":"54","author":"B Chang","year":"2016","unstructured":"Chang B, Li B, Huang A, et al. Changes of four common non-infectious liver diseases for the hospitalized patients in Beijing 302 hospital from 2002 to 2013. Alcohol. 2016;54:61\u201365","journal-title":"Alcohol"},{"key":"10633_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/liv.13535","volume":"38","author":"SR Tujios","year":"2018","unstructured":"Tujios SR, Lee WM. Acute liver failure induced by idiosyncratic reaction to drugs: challenges in diagnosis and therapy. Liver Int. 2018;38:6\u201314","journal-title":"Liver Int"},{"key":"10633_CR13","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547852\/. Accessed 1 Apr 2023"},{"key":"10633_CR14","first-page":"575","volume":"8","author":"Y Mao","year":"2014","unstructured":"Mao Y. HepaTox: a professional website that promotes clincial and translational research of DILI in China. Gan Zang. 2014;8:575\u2013576","journal-title":"Gan Zang"},{"key":"10633_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3350\/cmh.2019.1003","volume":"26","author":"EXS Low","year":"2020","unstructured":"Low EXS, Zheng Q, Chan E, Lim SG. Drug induced liver injury: east versus west\u2014a systematic review and meta-analysis. Clin Mol Hepatol. 2020;26:142\u2013154","journal-title":"Clin Mol Hepatol"},{"key":"10633_CR16","first-page":"688","volume":"49","author":"OA Marzuki","year":"2008","unstructured":"Marzuki OA, Fauzi ARM, Ayoub S, Kamarul IM. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. Singap Med J. 2008;49:688\u2013693","journal-title":"Singap Med J"},{"key":"10633_CR17","first-page":"88","volume":"11","author":"S Chirapongsathorn","year":"2023","unstructured":"Chirapongsathorn S, Sukeepaisarnjaroen W, Treeprasertsuk S, et al. Characteristics of drug-induced liver injury in chronic liver disease: results from the Thai Association for the Study of the Liver (THASL) DILI Registry. J Clin Transl Hepatol. 2023;11:88\u201396","journal-title":"J Clin Transl Hepatol"},{"key":"10633_CR18","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12906-016-1168-z","volume":"16","author":"DCH Teo","year":"2016","unstructured":"Teo DCH, Ng PSL, Tan SH, et al. Drug-induced liver injury associated with complementary and alternative medicine: a review of adverse event reports in an Asian community from 2009 to 2014. BMC Complement Altern Med. 2016;16:192","journal-title":"BMC Complement Altern Med"},{"key":"10633_CR19","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/JCMA.0000000000000648","volume":"85","author":"Y-S Huang","year":"2022","unstructured":"Huang Y-S, Tseng S-Y, Chen W-W, et al. Clinical characteristics and outcomes of drug-induced liver injury in Taiwan: with emphasis on the impact of chronic hepatitis B infection. J Chin Med Assoc. 2022;85:286\u2013294","journal-title":"J Chin Med Assoc"},{"key":"10633_CR20","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jceh.2020.11.002","volume":"11","author":"H Devarbhavi","year":"2021","unstructured":"Devarbhavi H, Joseph T, Sunil Kumar N, et al. The Indian network of drug-induced liver injury: etiology, clinical features, outcome and prognostic markers in 1288 patients. J Clin Exp Hepatol. 2021;11:288\u2013298","journal-title":"J Clin Exp Hepatol"},{"issue":"7","key":"10633_CR21","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","volume":"148","author":"N Chalasani","year":"2015","unstructured":"Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148(7):1340\u20131352","journal-title":"Gastroenterology"},{"key":"10633_CR22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1056\/NEJMra1816149","volume":"381","author":"JH Hoofnagle","year":"2019","unstructured":"Hoofnagle JH, Bj\u00f6rnsson ES. Drug-induced liver injury\u2014types and phenotypes. N Engl J Med. 2019;381:264\u2013273","journal-title":"N Engl J Med"},{"key":"10633_CR23","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","volume":"89","author":"GP Aithal","year":"2011","unstructured":"Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89:806\u2013815","journal-title":"Clin Pharmacol Ther"},{"key":"10633_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.627133","volume":"12","author":"Q Wang","year":"2021","unstructured":"Wang Q, Huang A, Wang J-B, Zou Z. Chronic drug-induced liver injury: updates and future challenges. Front Pharmacol. 2021;12: 627133","journal-title":"Front Pharmacol"},{"key":"10633_CR25","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/hep.26709","volume":"59","author":"DE Kleiner","year":"2014","unstructured":"Kleiner DE, Chalasani NP, Lee WM, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014;59:661\u2013670","journal-title":"Hepatology"},{"key":"10633_CR26","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"EASL Clinical Practice Guidelines","year":"2019","unstructured":"EASL Clinical Practice Guidelines. Drug-induced liver injury. J Hepatol. 2019;70:1222\u20131261","journal-title":"J Hepatol"},{"key":"10633_CR27","doi-asserted-by":"publisher","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","volume":"116","author":"NP Chalasani","year":"2021","unstructured":"Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2021;116:878\u2013898","journal-title":"Am J Gastroenterol"},{"key":"10633_CR28","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1002\/hep.22272","volume":"47","author":"C Lammert","year":"2008","unstructured":"Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008;47:2003\u20132009","journal-title":"Hepatology"},{"key":"10633_CR29","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jhep.2014.11.019","volume":"62","author":"MF Carrascosa","year":"2015","unstructured":"Carrascosa MF, Salcines-Caviedes JR, Lucena MI, Andrade RJ. Acute liver failure following atorvastatin dose escalation: is there a threshold dose for idiosyncratic hepatotoxicity? J Hepatol. 2015;62:751\u2013752","journal-title":"J Hepatol"},{"key":"10633_CR30","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.1016\/j.bmcl.2008.07.071","volume":"18","author":"JD Hughes","year":"2008","unstructured":"Hughes JD, Blagg J, Price DA, et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett. 2008;18:4872\u20134875","journal-title":"Bioorg Med Chem Lett"},{"key":"10633_CR31","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/hep.26208","volume":"58","author":"M Chen","year":"2013","unstructured":"Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology. 2013;58:388\u2013396","journal-title":"Hepatology"},{"key":"10633_CR32","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/hep.27206","volume":"60","author":"MD Aleo","year":"2014","unstructured":"Aleo MD, Luo Y, Swiss R, Bonin PD, Potter DM, Will Y. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology. 2014;60:1015\u20131022","journal-title":"Hepatology"},{"key":"10633_CR33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.hepres.2005.12.009","volume":"34","author":"S Tazuma","year":"2006","unstructured":"Tazuma S. Cyclosporin A and cholestasis: Its mechanism(s) and clinical relevancy. Hepatol Res. 2006;34:135\u2013136","journal-title":"Hepatol Res"},{"key":"10633_CR34","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/toxsci\/kfq269","volume":"118","author":"RE Morgan","year":"2010","unstructured":"Morgan RE, Trauner M, van Staden CJ, et al. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010;118:485\u2013500","journal-title":"Toxicol Sci"},{"key":"10633_CR35","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1124\/dmd.113.056267","volume":"42","author":"K Yu","year":"2014","unstructured":"Yu K, Geng X, Chen M, et al. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury. Drug Metab Dispos. 2014;42:744\u2013750","journal-title":"Drug Metab Dispos"},{"key":"10633_CR36","doi-asserted-by":"publisher","first-page":"1037814","DOI":"10.3389\/fphar.2022.1037814","volume":"13","author":"X Zhuang","year":"2022","unstructured":"Zhuang X, Li L, Liu T, et al. Mechanisms of isoniazid and rifampicin-induced liver injury and the effects of natural medicinal ingredients: a review. Front Pharmacol. 2022;13:1037814","journal-title":"Front Pharmacol"},{"key":"10633_CR37","unstructured":"Rifadin IV (rifampin for injection USP). [package insert]. 2010. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/050420s073,050627s012lbl.pdf. Accessed 31 Oct 2023"},{"key":"10633_CR38","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/S2468-1253(20)30006-6","volume":"5","author":"MI Lucena","year":"2020","unstructured":"Lucena MI, Sanabria J, Garc\u00eda-Cortes M, Stephens C, Andrade RJ. Drug-induced liver injury in older people. Lancet Gastroenterol Hepatol. 2020;5:862\u2013874","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10633_CR39","doi-asserted-by":"publisher","first-page":"238","DOI":"10.4103\/2249-4863.154661","volume":"4","author":"GS Gaude","year":"2015","unstructured":"Gaude GS, Chaudhury A, Hattiholi J. Drug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients. J Fam Med Prim Care. 2015;4:238\u2013243","journal-title":"J Fam Med Prim Care"},{"key":"10633_CR40","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/cpt.2108","volume":"109","author":"RA Weersink","year":"2021","unstructured":"Weersink RA, Alvarez-Alvarez I, Medina-C\u00e1liz I, et al. Clinical characteristics and outcome of drug-induced liver injury in the older patients: from the young-old to the oldest-old. Clin Pharmacol Ther. 2021;109:1147\u20131158","journal-title":"Clin Pharmacol Ther"},{"key":"10633_CR41","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jhep.2023.04.033","volume":"79","author":"RJ Andrade","year":"2023","unstructured":"Andrade RJ, Aithal GP, de Boer YS, et al. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): an expert opinion meeting report. J Hepatol. 2023;79:853\u2013866","journal-title":"J Hepatol"},{"key":"10633_CR42","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cgh.2017.12.036","volume":"16","author":"L Dakhoul","year":"2018","unstructured":"Dakhoul L, Ghabril M, Gu J, Navarro V, Chalasani N, Serrano J. Heavy consumption of alcohol is not associated with worse outcomes in patients with idiosyncratic drug-induced liver injury compared to non-drinkers. Clin Gastroenterol Hepatol. 2018;16:722\u2013729","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10633_CR43","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/0002-9343(65)90145-2","volume":"38","author":"CT Kunelis","year":"1965","unstructured":"Kunelis CT, Peters JL, Edmondson HA. Fatty liver of pregnancy and its relationship to tetracycline therapy. Am J Med. 1965;38:359\u2013377","journal-title":"Am J Med"},{"key":"10633_CR44","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1136\/bmj.38391.663287.E0","volume":"330","author":"S Bruno","year":"2005","unstructured":"Bruno S, Maisonneuve P, Castellana P, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ. 2005;330:932","journal-title":"BMJ"},{"key":"10633_CR45","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.jhep.2007.01.024","volume":"46","author":"P Rosenberg","year":"2007","unstructured":"Rosenberg P, Urwitz H, Johannesson A, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol. 2007;46:1111\u20131118","journal-title":"J Hepatol"},{"key":"10633_CR46","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/17425255.2021.1854726","volume":"17","author":"C Stephens","year":"2021","unstructured":"Stephens C, Lucena MI, Andrade RJ. Genetic risk factors in the development of idiosyncratic drug-induced liver injury. Expert Opin Drug Metab Toxicol. 2021;17:153\u2013169","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10633_CR47","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103\u2013141","journal-title":"Pharmacol Ther"},{"issue":"6","key":"10633_CR48","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1053\/j.gastro.2019.01.034","volume":"156","author":"ET Cirulli","year":"2019","unstructured":"Cirulli ET, Nicoletti P, Abramson K, et al. A missense variant in PTPN22 is a risk factor for drug-induced liver injury. Gastroenterology. 2019;156(6):1707\u20131716","journal-title":"Gastroenterology"},{"key":"10633_CR49","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.14309\/ajg.0000000000001913","volume":"117","author":"H Devarbhavi","year":"2022","unstructured":"Devarbhavi H, Kurien SS, Raj S, et al. Idiosyncratic drug-induced liver injury associated with and without drug reaction with eosinophilia and systemic symptoms. Am J Gastroenterol. 2022;117:1709\u20131713","journal-title":"Am J Gastroenterol"},{"key":"10633_CR50","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1111\/liv.14990","volume":"41","author":"Y-S Huang","year":"2021","unstructured":"Huang Y-S, Wu C-Y, Chang T-T, et al. Drug-induced liver injury associated with severe cutaneous adverse drug reactions: a nationwide study in Taiwan. Liver Int. 2021;41:2671\u20132680","journal-title":"Liver Int"},{"key":"10633_CR51","unstructured":"Drug-induced liver injury (DILI): current status and future directions for drug development and the post-market setting. A consensus by a CIOMS Working Group. Geneva, Switzerland: Council for International Organizations of Medical Sciences (CIOMS). 2020. https:\/\/cioms.ch\/wp-content\/uploads\/2020\/06\/CIOMS_DILI_Web_16Jun2020.pdf. Accessed 1 Apr 2023"},{"key":"10633_CR52","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jhep.2021.12.043","volume":"76","author":"J Ahmad","year":"2022","unstructured":"Ahmad J, Barnhart HX, Bonacini M, et al. Value of liver biopsy in the diagnosis of drug-induced liver injury. J Hepatol. 2022;76:1070\u20131078","journal-title":"J Hepatol"},{"key":"10633_CR53","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1055\/s-0029-1240005","volume":"29","author":"DE Kleiner","year":"2009","unstructured":"Kleiner DE. The pathology of drug-induced liver injury. Semin Liver Dis. 2009;29:364\u2013372","journal-title":"Semin Liver Dis"},{"key":"10633_CR54","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1038\/s41379-019-0314-9","volume":"32","author":"Q-J Tian","year":"2019","unstructured":"Tian Q-J, Zhao X-Y, Wang Y, et al. Histologic pattern is better correlated with clinical outcomes than biochemical classification in patients with drug-induced liver injury. Mod Pathol. 2019;32:1795\u20131805","journal-title":"Mod Pathol"},{"key":"10633_CR55","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/j.1365-2036.2008.03655.x","volume":"27","author":"M Garc\u00eda-Cort\u00e9s","year":"2008","unstructured":"Garc\u00eda-Cort\u00e9s M, Lucena MI, Pachkoria K, Borraz Y, Hidalgo R, Andrade RJ. Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther. 2008;27:780\u2013789","journal-title":"Aliment Pharmacol Ther"},{"key":"10633_CR56","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1053\/jhep.2001.20645","volume":"33","author":"MI Lucena","year":"2001","unstructured":"Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, De La Cuesta FS. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001;33:123\u2013130","journal-title":"Hepatology"},{"key":"10633_CR57","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","volume":"46","author":"G Danan","year":"1993","unstructured":"Danan G, Benichou C. Causality assessment of adverse reactions to drugs\u2014I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323\u20131330","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10633_CR58","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ijms17010014","volume":"17","author":"G Danan","year":"2015","unstructured":"Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015;17(1):14","journal-title":"Int J Mol Sci"},{"key":"10633_CR59","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s12072-021-10144-3","volume":"15","author":"H Devarbhavi","year":"2021","unstructured":"Devarbhavi H, Aithal G, Treeprasertsuk S, et al. Drug-induced liver injury: Asia Pacific Association of Study of liver consensus guidelines. Hepatol Int. 2021;15:258\u2013282","journal-title":"Hepatol Int"},{"key":"10633_CR60","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/hep.32327","volume":"76","author":"PH Hayashi","year":"2022","unstructured":"Hayashi PH, Lucena MI, Fontana RJ, et al. A revised electronic version of RUCAM for the diagnosis of DILI. Hepatology. 2022;76:18\u201331","journal-title":"Hepatology"},{"key":"10633_CR61","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.14309\/ajg.0000000000001836","volume":"117","author":"PH Hayashi","year":"2022","unstructured":"Hayashi PH, Lucena MI, Fontana RJ. RECAM: a new and improved, computerized causality assessment tool for DILI diagnosis. Am J Gastroenterol. 2022;117:1387\u20131389","journal-title":"Am J Gastroenterol"},{"key":"10633_CR62","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/hep.23577","volume":"51","author":"DC Rockey","year":"2010","unstructured":"Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel\u2013Uclaf causality assessment method. Hepatology. 2010;51:2117\u20132126","journal-title":"Hepatology"},{"key":"10633_CR63","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/hep.29152","volume":"66","author":"CM Hunt","year":"2017","unstructured":"Hunt CM, Papay JI, Stanulovic V, Regev A. Drug rechallenge following drug-induced liver injury. Hepatology. 2017;66:646\u2013654","journal-title":"Hepatology"},{"key":"10633_CR64","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/hep.20800","volume":"42","author":"E Bj\u00f6rnsson","year":"2005","unstructured":"Bj\u00f6rnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42:481\u2013489","journal-title":"Hepatology"},{"key":"10633_CR65","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s12072-022-10405-9","volume":"17","author":"Y Wang","year":"2023","unstructured":"Wang Y, Zou C, Wee A, et al. Comparison of the prognostic models for mortality in idiosyncratic drug-induced liver injury. Hepatol Int. 2023;17:488\u2013498","journal-title":"Hepatol Int"},{"key":"10633_CR66","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/hep.29283","volume":"66","author":"PH Hayashi","year":"2017","unstructured":"Hayashi PH, Rockey DC, Fontana RJ, et al. Death and liver transplantation within 2 years of onset of drug-induced liver injury. Hepatology. 2017;66:1275\u20131285","journal-title":"Hepatology"},{"key":"10633_CR67","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s11096-018-0698-5","volume":"40","author":"J-H Ye","year":"2018","unstructured":"Ye J-H, Ho Y-F, On AWF, et al. Trends in reporting drug-associated liver injuries in Taiwan: a focus on amiodarone. Int J Clin Pharm. 2018;40:911\u2013920","journal-title":"Int J Clin Pharm"},{"key":"10633_CR68","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1016\/j.clcc.2017.09.004","volume":"17","author":"H Uetake","year":"2018","unstructured":"Uetake H, Sugihara K, Muro K, Sunaya T, Horiuchi-Yamamoto Y, Takikawa H. Clinical features of Regorafenib-induced liver injury in Japanese patients from postmarketing experience. Clin Colorectal Cancer. 2018;17:e49\u2013e58","journal-title":"Clin Colorectal Cancer"},{"key":"10633_CR69","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.cgh.2016.03.046","volume":"14","author":"DG Koch","year":"2016","unstructured":"Koch DG, Tillman H, Durkalski V, Lee WM, Reuben A. Development of a model to predict transplant-free survival\u00a0of\u00a0patients with acute liver failure. Clin Gastroenterol Hepatol. 2016;14:1199\u20131206","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10633_CR70","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10541-w","author":"L Han","year":"2023","unstructured":"Han L, Huang A, Chen J, et al. Clinical characteristics and prognosis of non-APAP drug-induced acute liver failure: a large multicenter cohort study. Hepatol Int. 2023. https:\/\/doi.org\/10.1007\/s12072-023-10541-w","journal-title":"Hepatol Int"},{"issue":"5","key":"10633_CR71","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1053\/j.gastro.2019.07.006","volume":"157","author":"M Ghabril","year":"2019","unstructured":"Ghabril M, Gu J, Yoder L, et al. Development and validation of a model consisting of comorbidity burden to calculate risk of death within 6 months for patients with suspected drug-induced liver injury. Gastroenterology. 2019;157(5):1245\u20131252","journal-title":"Gastroenterology"},{"key":"10633_CR72","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/hep.32283","volume":"75","author":"C-Y Wang","year":"2022","unstructured":"Wang C-Y, Deng Y, Li P, et al. Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: a large multicenter study. Hepatology. 2022;75:1373\u20131385","journal-title":"Hepatology"},{"issue":"1","key":"10633_CR73","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2014.03.045","volume":"147","author":"RJ Fontana","year":"2014","unstructured":"Fontana RJ, Hayashi PH, Gu J, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology. 2014;147(1):96\u2013108","journal-title":"Gastroenterology"},{"key":"10633_CR74","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/hep.28967","volume":"65","author":"HL Bonkovsky","year":"2017","unstructured":"Bonkovsky HL, Kleiner DE, Gu J, et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology. 2017;65:1267\u20131277","journal-title":"Hepatology"},{"key":"10633_CR75","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1055\/s-0034-1375960","volume":"34","author":"DE Amacher","year":"2014","unstructured":"Amacher DE, Chalasani N. Drug-induced hepatic steatosis. Semin Liver Dis. 2014;34:205\u2013214","journal-title":"Semin Liver Dis"},{"key":"10633_CR76","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1055\/s-0034-1375963","volume":"34","author":"M Ghabril","year":"2014","unstructured":"Ghabril M, Vuppalanchi R. Drug-induced nodular regenerative hyperplasia. Semin Liver Dis. 2014;34:240\u2013245","journal-title":"Semin Liver Dis"},{"key":"10633_CR77","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.forsciint.2004.05.010","volume":"149","author":"M Tsokos","year":"2005","unstructured":"Tsokos M, Erbersdobler A. Pathology of peliosis. Forensic Sci Int. 2005;149:25\u201333","journal-title":"Forensic Sci Int"},{"key":"10633_CR78","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jhep.2016.05.003","volume":"65","author":"I Medina-Caliz","year":"2016","unstructured":"Medina-Caliz I, Robles-Diaz M, Garcia-Mu\u00f1oz B, et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. J Hepatol. 2016;65:532\u2013542","journal-title":"J Hepatol"},{"key":"10633_CR79","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/ajg.2015.283","volume":"110","author":"RJ Fontana","year":"2015","unstructured":"Fontana RJ, Hayashi PH, Barnhart H, et al. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. Am J Gastroenterol. 2015;110:1450\u20131459","journal-title":"Am J Gastroenterol"},{"key":"10633_CR80","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jhep.2012.03.016","volume":"57","author":"G Crespo","year":"2012","unstructured":"Crespo G, Fern\u00e1ndez-Varo G, Mari\u00f1o Z, et al. ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study. J Hepatol. 2012;57:281\u2013287","journal-title":"J Hepatol"},{"key":"10633_CR81","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jhep.2018.01.001","volume":"69","author":"L Dakhoul","year":"2018","unstructured":"Dakhoul L, Ghabril M, Chalasani N. Drug-induced chronic liver injury. J Hepatol. 2018;69:248\u2013250","journal-title":"J Hepatol"},{"key":"10633_CR82","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/hep.32689","volume":"77","author":"RJ Fontana","year":"2023","unstructured":"Fontana RJ, Liou I, Reuben A, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023;77:1036\u20131065","journal-title":"Hepatology"},{"key":"10633_CR83","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1002\/hep.23588","volume":"51","author":"E Bj\u00f6rnsson","year":"2010","unstructured":"Bj\u00f6rnsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51:2040\u20132048","journal-title":"Hepatology"},{"key":"10633_CR84","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.cgh.2017.05.027","volume":"15","author":"ES Bj\u00f6rnsson","year":"2017","unstructured":"Bj\u00f6rnsson ES, Bergmann O, Jonasson JG, Grondal G, Gudbjornsson B, Olafsson S. Drug-induced autoimmune hepatitis: response to corticosteroids and lack of relapse after cessation of steroids. Clin Gastroenterol Hepatol. 2017;15:1635\u20131636","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10633_CR85","unstructured":"Hepatobiliary Cooperative Group of Chinese Society of Gastroenterology. Expert consensus on diagnosis and treatment of pyrrolidine alkaloids-related sinusoidal obstruction syndrome (2017, Nanjing). Zhong Hua Xiao Hua Za Zhi. 2017;513\u201322."},{"key":"10633_CR86","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3390\/toxins13120849","volume":"13","author":"Z Wang","year":"2021","unstructured":"Wang Z, Han H, Wang C, et al. Hepatotoxicity of pyrrolizidine alkaloid compound intermedine: comparison with other pyrrolizidine alkaloids and its toxicological mechanism. Toxins (Basel). 2021;13:849","journal-title":"Toxins (Basel)"},{"key":"10633_CR87","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.3748\/wjg.v25.i28.3753","volume":"25","author":"X-Q Yang","year":"2019","unstructured":"Yang X-Q, Ye J, Li X, Li Q, Song Y-H. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes. World J Gastroenterol. 2019;25:3753\u20133763","journal-title":"World J Gastroenterol"},{"key":"10633_CR88","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.toxlet.2020.01.021","volume":"323","author":"Y Chen","year":"2020","unstructured":"Chen Y, Xiong F, Wang W, et al. The long persistence of pyrrolizidine alkaloid-derived pyrrole-protein adducts in vivo: Kinetic study following multiple exposures of a pyrrolizidine alkaloid containing extract of Gynura japonica. Toxicol Lett. 2020;323:41\u201347","journal-title":"Toxicol Lett"},{"key":"10633_CR89","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/jgh.14612","volume":"34","author":"Y Zhuge","year":"2019","unstructured":"Zhuge Y, Liu Y, Xie W, Zou X, Xu J, Wang J. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. J Gastroenterol Hepatol. 2019;34:634\u2013642","journal-title":"J Gastroenterol Hepatol"},{"key":"10633_CR90","first-page":"345","volume":"9","author":"W Zhang","year":"2021","unstructured":"Zhang W, Liu L, Zhang M, et al. Validation of the Nanjing criteria for diagnosing pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome. J Clin Transl Hepatol. 2021;9:345\u2013352","journal-title":"J Clin Transl Hepatol"},{"key":"10633_CR91","doi-asserted-by":"publisher","first-page":"4861","DOI":"10.2147\/DDDT.S87858","volume":"9","author":"H Gao","year":"2015","unstructured":"Gao H, Ruan JQ, Chen J, et al. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome. Drug Des Dev Ther. 2015;9:4861\u20134868","journal-title":"Drug Des Dev Ther"},{"key":"10633_CR92","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s12072-021-10293-5","volume":"16","author":"X Wang","year":"2022","unstructured":"Wang X, Zhang W, Zhang M, et al. Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. Hepatol Int. 2022;16:669\u2013679","journal-title":"Hepatol Int"},{"key":"10633_CR93","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3389\/fimmu.2020.00489","volume":"11","author":"F Bonifazi","year":"2020","unstructured":"Bonifazi F, Barbato F, Ravaioli F, et al. Diagnosis and treatment of VOD\/SOS after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2020;11:489","journal-title":"Front Immunol"},{"key":"10633_CR94","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/bjh.12558","volume":"163","author":"FL Dignan","year":"2013","unstructured":"Dignan FL, Wynn RF, Hadzic N, et al. BCSH\/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol. 2013;163:444\u2013457","journal-title":"Br J Haematol"},{"key":"10633_CR95","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/bmt.2015.52","volume":"50","author":"M Mohty","year":"2015","unstructured":"Mohty M, Malard F, Abecassis M, et al. Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015;50:781\u2013789","journal-title":"Bone Marrow Transplant"},{"key":"10633_CR96","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1111\/jvh.13751","volume":"29","author":"C Chou","year":"2022","unstructured":"Chou C, Veracruz N, Chitnis AS, Wong RJ. Risk of drug-induced liver injury in chronic hepatitis B and tuberculosis co-infection: a systematic review and meta-analysis. J Viral Hepat. 2022;29:1107\u20131114","journal-title":"J Viral Hepat"},{"key":"10633_CR97","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12879-016-1344-2","volume":"16","author":"WS Kim","year":"2016","unstructured":"Kim WS, Lee SS, Lee CM, et al. Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury. BMC Infect Dis. 2016;16:50","journal-title":"BMC Infect Dis"},{"key":"10633_CR98","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268820002861","volume":"148","author":"J Zheng","year":"2020","unstructured":"Zheng J, Guo M-H, Peng H-W, Cai X-L, Wu Y-L, Peng X-E. The role of hepatitis B infection in anti-tuberculosis drug-induced liver injury: a meta-analysis of cohort studies. Epidemiol Infect. 2020;148: e290","journal-title":"Epidemiol Infect"},{"key":"10633_CR99","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jama.283.1.74","volume":"283","author":"MS Sulkowski","year":"2000","unstructured":"Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74\u201380","journal-title":"JAMA"},{"key":"10633_CR100","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/hep.23716","volume":"52","author":"M N\u00fa\u00f1ez","year":"2010","unstructured":"N\u00fa\u00f1ez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology. 2010;52:1143\u20131155","journal-title":"Hepatology"},{"key":"10633_CR101","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1016\/j.cgh.2018.12.013","volume":"17","author":"C Lammert","year":"2019","unstructured":"Lammert C, Imler T, Teal E, Chalasani N. Patients with chronic liver disease suggestive of nonalcoholic fatty liver disease may be at higher risk for drug-induced liver injury. Clin Gastroenterol Hepatol. 2019;17:2814\u20132815","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10633_CR102","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.2147\/IDR.S326386","volume":"14","author":"Y-H Liu","year":"2021","unstructured":"Liu Y-H, Guo Y, Xu H, Feng H, Chen D-Y. Impact of non-alcoholic simple fatty liver disease on antituberculosis drug-induced liver injury. Infect Drug Resist. 2021;14:3667\u20133671","journal-title":"Infect Drug Resist"},{"key":"10633_CR103","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/j.1872-034X.2007.00072.x","volume":"37","author":"G Tarantino","year":"2007","unstructured":"Tarantino G, Conca P, Basile V, et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res. 2007;37:410\u2013415","journal-title":"Hepatol Res"},{"key":"10633_CR104","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","volume":"126","author":"N Chalasani","year":"2004","unstructured":"Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:1287\u20131292","journal-title":"Gastroenterology"},{"key":"10633_CR105","doi-asserted-by":"publisher","first-page":"77C","DOI":"10.1016\/j.amjcard.2005.12.014","volume":"97","author":"DE Cohen","year":"2006","unstructured":"Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97:77C-81C","journal-title":"Am J Cardiol"},{"key":"10633_CR106","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/hep.21848","volume":"46","author":"JH Lewis","year":"2007","unstructured":"Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007;46:1453\u20131463","journal-title":"Hepatology"},{"key":"10633_CR107","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jhep.2016.01.007","volume":"64","author":"JH Hoofnagle","year":"2016","unstructured":"Hoofnagle JH. Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C. J Hepatol. 2016;64:763\u2013765","journal-title":"J Hepatol"},{"key":"10633_CR108","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Obeticholic Acid. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548806\/. Accessed 10 Dec 2019."},{"key":"10633_CR109","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1164\/ajrccm.157.6.9711039","volume":"157","author":"JR Ungo","year":"1998","unstructured":"Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157:1871\u20131876","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10633_CR110","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cgh.2017.12.036","volume":"16","author":"L Dakhoul","year":"2018","unstructured":"Dakhoul L, Ghabril M, Gu J, Navarro V, Chalasani N, Serrano J. Heavy consumption of alcohol is not associated with worse outcomes in patients with idiosyncratic drug-induced liver injury compared to non-drinkers. Clin Gastroenterol Hepatol. 2018;16(5):722\u2013729","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10633_CR111","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12876-016-0550-0","volume":"16","author":"A Sobhonslidsuk","year":"2016","unstructured":"Sobhonslidsuk A, Poovorawan K, Soonthornworasiri N, Pan-Ngum W, Phaosawasdi K. The incidence, presentation, outcomes, risk of mortality and economic data of drug-induced liver injury from a national database in Thailand: a population-base study. BMC Gastroenterol. 2016;16:135","journal-title":"BMC Gastroenterol"},{"key":"10633_CR112","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","volume":"15","author":"G Lau","year":"2021","unstructured":"Lau G, Yu M-L, Wong G, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int. 2021;15:1031\u20131048","journal-title":"Hepatol Int"},{"issue":"1","key":"10633_CR113","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","volume":"148","author":"RP Perrillo","year":"2015","unstructured":"Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221\u2013244","journal-title":"Gastroenterology"},{"key":"10633_CR114","first-page":"769","volume":"9","author":"G Wang","year":"2021","unstructured":"Wang G, Duan Z. Guidelines for prevention and treatment of chronic hepatitis B. J Clin Transl Hepatol. 2021;9:769\u2013791","journal-title":"J Clin Transl Hepatol"},{"key":"10633_CR115","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/apt.16611","volume":"54","author":"Z Liu","year":"2021","unstructured":"Liu Z, Jin Q, Zhang Y, et al. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther. 2021;54:1134\u20131149","journal-title":"Aliment Pharmacol Ther"},{"key":"10633_CR116","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u20131599","journal-title":"Hepatology"},{"key":"10633_CR117","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/hepr.13288","volume":"49","author":"M Aiso","year":"2019","unstructured":"Aiso M, Takikawa H, Tsuji K, et al. Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan. Hepatol Res. 2019;49:105\u2013110","journal-title":"Hepatol Res"},{"key":"10633_CR118","first-page":"354","volume":"34","author":"C Zhu","year":"2018","unstructured":"Zhu C, Wang H, Yuan J. Clinical features of drug-induced liver injury: an analysis of 445 cases. Lin Chuang Gan Dan Bing Za Zhi. 2018;34:354\u2013358","journal-title":"Lin Chuang Gan Dan Bing Za Zhi"},{"key":"10633_CR119","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/MEG.0b013e32835f6889","volume":"25","author":"Y Zhou","year":"2013","unstructured":"Zhou Y, Yang L, Liao Z, He X, Zhou Y, Guo H. Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21,789 patients. Eur J Gastroenterol Hepatol. 2013;25:825\u2013829","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10633_CR120","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1007\/s12072-021-10241-3","volume":"15","author":"Y-S Huang","year":"2021","unstructured":"Huang Y-S, Chang T-T, Peng C-Y, et al. Herbal and dietary supplement-induced liver injury in Taiwan: comparison with conventional drug-induced liver injury. Hepatol Int. 2021;15:1456\u20131465","journal-title":"Hepatol Int"},{"key":"10633_CR121","doi-asserted-by":"crossref","first-page":"263","DOI":"10.14218\/JCTH.2019.00043","volume":"7","author":"CA Philips","year":"2019","unstructured":"Philips CA, Augustine P, Rajesh S, Praveen Kumar Y, Madhu D. Complementary and alternative medicine-related drug-induced liver injury in Asia. J Clin Transl Hepatol. 2019;7:263\u2013274","journal-title":"J Clin Transl Hepatol"},{"key":"10633_CR122","doi-asserted-by":"publisher","first-page":"574","DOI":"10.4254\/wjh.v12.i9.574","volume":"12","author":"CA Philips","year":"2020","unstructured":"Philips CA, Ahamed R, Rajesh S, George T, Mohanan M, Augustine P. Comprehensive review of hepatotoxicity associated with traditional Indian Ayurvedic herbs. World J Hepatol. 2020;12:574\u2013595","journal-title":"World J Hepatol"},{"key":"10633_CR123","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/hep.27317","volume":"60","author":"VJ Navarro","year":"2014","unstructured":"Navarro VJ, Barnhart H, Bonkovsky HL, et al. Liver injury from herbals and dietary supplements in the US drug-induced liver injury network. Hepatology. 2014;60:1399\u20131408","journal-title":"Hepatology"},{"key":"10633_CR124","doi-asserted-by":"publisher","first-page":"e548","DOI":"10.1016\/j.cgh.2021.01.011","volume":"20","author":"F Bessone","year":"2022","unstructured":"Bessone F, Garc\u00eda-Cort\u00e9s M, Medina-Caliz I, et al. Herbal and dietary supplements-induced liver injury in latin America: experience from the LATINDILI network. Clin Gastroenterol Hepatol. 2022;20:e548\u2013e563","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10633_CR125","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/apt.13023","volume":"41","author":"M Robles-Diaz","year":"2015","unstructured":"Robles-Diaz M, Gonzalez-Jimenez A, Medina-Caliz I, et al. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Aliment Pharmacol Ther. 2015;41:116\u2013125","journal-title":"Aliment Pharmacol Ther"},{"key":"10633_CR126","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3389\/fphar.2017.00349","volume":"8","author":"L Lin","year":"2017","unstructured":"Lin L, Li H, Lin H, et al. A new perspective on liver injury by traditional chinese herbs such as\u202f: the geographical area of harvest as an important contributory factor. Front Pharmacol. 2017;8:349","journal-title":"Front Pharmacol"},{"key":"10633_CR127","first-page":"333","volume":"41","author":"H-R Cui","year":"2016","unstructured":"Cui H-R, Bai Z-F, Song H-B, Jia T-Z, Wang J-B, Xiao X-H. Investigation of potential toxic factors for fleece-flower root: from perspective of processing methods evolution. Zhong Guo Zhong Yao Za Zhi. 2016;41:333\u2013339","journal-title":"Zhong Guo Zhong Yao Za Zhi"},{"key":"10633_CR128","first-page":"80","volume":"2","author":"R Teschke","year":"2014","unstructured":"Teschke R. Traditional Chinese medicine induced liver injury. J Clin Transl Hepatol. 2014;2:80\u201394","journal-title":"J Clin Transl Hepatol"},{"key":"10633_CR129","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fphar.2012.00069","volume":"3","author":"PS Fasinu","year":"2012","unstructured":"Fasinu PS, Bouic PJ, Rosenkranz B. An overview of the evidence and mechanisms of herb-drug interactions. Front Pharmacol. 2012;3:69","journal-title":"Front Pharmacol"},{"key":"10633_CR130","first-page":"2983","volume":"39","author":"S-X Wu","year":"2014","unstructured":"Wu S-X, Sun H-F, Yang X-H, et al. \u201cRe-evaluation upon suspected event\u201d is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations. Zhong Guo Zhong Yao Za Zhi. 2014;39:2983\u20132988","journal-title":"Zhong Guo Zhong Yao Za Zhi"},{"key":"10633_CR131","first-page":"189","volume-title":"Huang Di Nei Jing Su Wen","author":"D Tian","year":"2005","unstructured":"Tian D. Huang Di Nei Jing Su Wen. Beijing: People\u2019s Medical Publishing House; 2005. p. 189\u2013190"},{"key":"10633_CR132","unstructured":"Key technical issues of herbal medicines with reference to interaction with other medicines. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. https:\/\/www.who.int\/publications\/i\/item\/9789240019140."},{"key":"10633_CR133","unstructured":"Song H-B, Han L. Epidemiologic characteristics, risk factors and safety evaluation of traditional Chinese medicine induced liver injury. Zhong Guo Yao Li Xue Yu Du Li Xue Za Zhi. 2016;30:291\u2013305"},{"key":"10633_CR134","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.cgh.2017.12.051","volume":"16","author":"I Medina-Caliz","year":"2018","unstructured":"Medina-Caliz I, Garcia-Cortes M, Gonzalez-Jimenez A, et al. Herbal and dietary supplement-induced liver injuries in the Spanish DILI Registry. Clin Gastroenterol Hepatol. 2018;16:1495\u20131502","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10633_CR135","doi-asserted-by":"publisher","first-page":"617","DOI":"10.14309\/ajg.0000000000001655","volume":"117","author":"A Rao","year":"2022","unstructured":"Rao A, Rule JA, Hameed B, Ganger D, Fontana RJ, Lee WM. Secular trends in severe idiosyncratic drug-induced liver injury in North America: an update from the acute liver failure study group registry. Am J Gastroenterol. 2022;117:617\u2013626","journal-title":"Am J Gastroenterol"},{"key":"10633_CR136","unstructured":"China State Drug Administration. Technical guidelines for clinical evaluation of liver injury induced by traditional Chinese medicine. Lin Chuang Gan Dan Bing Za Zhi 2018;34:1403\u20139"},{"key":"10633_CR137","unstructured":"Chinese society for tuberculosis. Guidelines for anti-tuberculosis drug-induced liver injury (2019 version). Zhong Hua Jie He He Hu Xi Za Zhi. 2019;42:343\u201356"},{"key":"10633_CR138","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1038\/ajg.2010.287","volume":"105","author":"H Devarbhavi","year":"2010","unstructured":"Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol. 2010;105:2396\u20132404","journal-title":"Am J Gastroenterol"},{"key":"10633_CR139","doi-asserted-by":"publisher","first-page":"929","DOI":"10.14309\/ajg.0000000000000201","volume":"114","author":"H Devarbhavi","year":"2019","unstructured":"Devarbhavi H, Choudhury AK, Sharma MK, et al. Drug-induced acute-on-chronic liver failure in Asian Patients. Am J Gastroenterol. 2019;114:929\u2013937","journal-title":"Am J Gastroenterol"},{"key":"10633_CR140","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/cpt.2100","volume":"109","author":"P Nicoletti","year":"2021","unstructured":"Nicoletti P, Devarbhavi H, Goel A, et al. Genetic risk factors in drug-induced liver injury due to isoniazid-containing antituberculosis drug regimens. Clin Pharmacol Ther. 2021;109:1125\u20131135","journal-title":"Clin Pharmacol Ther"},{"key":"10633_CR141","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1440-1746.2012.07279.x","volume":"28","author":"H Devarbhavi","year":"2013","unstructured":"Devarbhavi H, Singh R, Patil M, Sheth K, Adarsh CK, Balaraju G. Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury. J Gastroenterol Hepatol. 2013;28:161\u2013167","journal-title":"J Gastroenterol Hepatol"},{"key":"10633_CR142","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12879-017-2330-z","volume":"17","author":"A Abbara","year":"2017","unstructured":"Abbara A, Chitty S, Roe JK, et al. Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK. BMC Infect Dis. 2017;17:231","journal-title":"BMC Infect Dis"},{"key":"10633_CR143","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1093\/cid\/ciw376","volume":"63","author":"P Nahid","year":"2016","unstructured":"Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63:e147\u2013e195","journal-title":"Clin Infect Dis"},{"key":"10633_CR144","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947\u2013957","journal-title":"N Engl J Med"},{"key":"10633_CR145","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121\u2013128","journal-title":"Lancet Oncol"},{"key":"10633_CR146","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380\u20132388","journal-title":"N Engl J Med"},{"key":"10633_CR147","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239\u2013246","journal-title":"Lancet Oncol"},{"key":"10633_CR148","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","volume":"15","author":"Y-L Wu","year":"2014","unstructured":"Wu Y-L, Zhou C, Hu C-P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213\u2013222","journal-title":"Lancet Oncol"},{"key":"10633_CR149","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1093\/annonc\/mdx359","volume":"28","author":"YK Shi","year":"2017","unstructured":"Shi YK, Wang L, Han BH, et al. First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol. 2017;28:2443\u20132450","journal-title":"Ann Oncol"},{"key":"10633_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108256","volume":"237","author":"Q Zhao","year":"2022","unstructured":"Zhao Q, Wu ZE, Li B, Li F. Recent advances in metabolism and toxicity of tyrosine kinase inhibitors. Pharmacol Ther. 2022;237: 108256","journal-title":"Pharmacol Ther"},{"key":"10633_CR151","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","volume":"56","author":"SE Coutr\u00e9","year":"2015","unstructured":"Coutr\u00e9 SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56:2779\u20132786","journal-title":"Leuk Lymphoma"},{"key":"10633_CR152","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/hep.31227","volume":"72","author":"TB Peeraphatdit","year":"2020","unstructured":"Peeraphatdit TB, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR. Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation. Hepatology. 2020;72:315\u2013329","journal-title":"Hepatology"},{"key":"10633_CR153","first-page":"175","volume":"28","author":"XH Lei","year":"2020","unstructured":"Lei XH, Tang YY, Li J, Mao YM. Hepatotoxicity associated with tumor immune checkpoint inhibitors. (Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi) Chin J Hepatol. 2020;28:175\u2013178","journal-title":"(Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi) Chin J Hepatol"},{"key":"10633_CR154","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/liv.13746","volume":"38","author":"DL Suzman","year":"2018","unstructured":"Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int. 2018;38:976\u2013987","journal-title":"Liver Int"},{"key":"10633_CR155","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","volume":"68","author":"E De Martin","year":"2018","unstructured":"De Martin E, Michot J-M, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018;68:1181\u20131190","journal-title":"J Hepatol"},{"key":"10633_CR156","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/CMR.0000000000000366","volume":"27","author":"S Yildirim","year":"2017","unstructured":"Yildirim S, Deniz K, Do\u011fan E, Ba\u015fkol M, G\u00fcrsoy \u015e, \u00d6zkan M. Ipilimumab-associated cholestatic hepatitis: a case report and literature review. Melanoma Res. 2017;27:380\u2013382","journal-title":"Melanoma Res"},{"key":"10633_CR157","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1002\/hep.30157","volume":"68","author":"J LoPiccolo","year":"2018","unstructured":"LoPiccolo J, Brener MI, Oshima K, Lipson EJ, Hamilton JP. Nodular regenerative hyperplasia associated with immune checkpoint blockade. Hepatology. 2018;68:2431\u20132433","journal-title":"Hepatology"},{"key":"10633_CR158","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1097\/COC.0000000000000374","volume":"41","author":"BM Huffman","year":"2018","unstructured":"Huffman BM, Kottschade LA, Kamath PS, Markovic SN. Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management. Am J Clin Oncol. 2018;41:760\u2013765","journal-title":"Am J Clin Oncol"},{"key":"10633_CR159","unstructured":"Yervoy (Ipilimumab) Prescribing Information. 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125377s073lbl.pdf. Accessed 1 Apr 2023"},{"key":"10633_CR160","unstructured":"Imfinzi (Durvalumab) Prescribing Information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761069s018lbl.pdf. Accessed 1 Apr 2023"},{"key":"10633_CR161","unstructured":"Tecentriq (Atezolizumab) Prescribing Information. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761034s042lbl.pdf. Accessed 1 Apr 2023"},{"key":"10633_CR162","unstructured":"Bavencio (Avelumab) Prescribing Information. 2019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761049s006lbl.pdf. Accessed 1 Apr 2023"},{"key":"10633_CR163","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10620-012-2140-5","volume":"57","author":"DE Kleiner","year":"2012","unstructured":"Kleiner DE, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci. 2012;57:2233\u20132240","journal-title":"Dig Dis Sci"},{"key":"10633_CR164","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158\u2013168","journal-title":"N Engl J Med"},{"key":"10633_CR165","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2:234\u2013240","journal-title":"JAMA Oncol"},{"key":"10633_CR166","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","volume":"28","author":"AM Menzies","year":"2017","unstructured":"Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28:368\u2013376","journal-title":"Ann Oncol"},{"key":"10633_CR167","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7326\/M17-2073","volume":"168","author":"N Abdel-Wahab","year":"2018","unstructured":"Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med. 2018;168:121\u2013130","journal-title":"Ann Intern Med"},{"key":"10633_CR168","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/hep.32215","volume":"75","author":"M Li","year":"2022","unstructured":"Li M, Wong D, Vogel AS, et al. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. Hepatology. 2022;75:531\u2013540","journal-title":"Hepatology"},{"key":"10633_CR169","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1217\u20131238","journal-title":"Ann Oncol"},{"key":"10633_CR170","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073\u20134126","journal-title":"J Clin Oncol"},{"key":"10633_CR171","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jhep.2016.11.015","volume":"66","author":"M Ziemer","year":"2017","unstructured":"Ziemer M, Koukoulioti E, Beyer S, Simon JC, Berg T. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Hepatol. 2017;66:657\u2013659","journal-title":"J Hepatol"},{"key":"10633_CR172","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/ccr3.3597","volume":"9","author":"G Omori","year":"2021","unstructured":"Omori G, Takada K, Murase K, et al. Successful mycophenolate mofetil treatment of a patient with severe steroid-refractory hepatitis evoked by nivolumab plus ipilimumab treatment for relapsed bladder cancer. Clin Case Rep. 2021;9:654\u2013659","journal-title":"Clin Case Rep"},{"key":"10633_CR173","unstructured":"US Department Of Health And Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. 2009. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed 1 Apr 2023"},{"key":"10633_CR174","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S2468-1253(17)30266-2","volume":"3","author":"JW Dear","year":"2018","unstructured":"Dear JW, Clarke JI, Francis B, et al. Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies. Lancet Gastroenterol Hepatol. 2018;3:104\u2013113","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10633_CR175","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/hep.27265","volume":"60","author":"MR McGill","year":"2014","unstructured":"McGill MR, Staggs VS, Sharpe MR, Lee WM, Jaeschke H. Serum mitochondrial biomarkers and damage-associated molecular patterns are higher in acetaminophen overdose patients with poor outcome. Hepatology. 2014;60:1336\u20131345","journal-title":"Hepatology"},{"key":"10633_CR176","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1517\/14740338.2016.1160057","volume":"15","author":"JI Clarke","year":"2016","unstructured":"Clarke JI, Dear JW, Antoine DJ. Recent advances in biomarkers and therapeutic interventions for hepatic drug safety\u2014false dawn or new horizon? Expert Opin Drug Saf. 2016;15:625\u2013634","journal-title":"Expert Opin Drug Saf"},{"key":"10633_CR177","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/hep.29802","volume":"69","author":"RJ Church","year":"2019","unstructured":"Church RJ, Kullak-Ublick GA, Aubrecht J, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort. Hepatology. 2019;69:760\u2013773","journal-title":"Hepatology"},{"key":"10633_CR178","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/hep.30660","volume":"70","author":"C Li","year":"2019","unstructured":"Li C, Rao T, Chen X, et al. HLA-B*35:01 allele is a potential biomarker for predicting polygonum multiflorum-induced liver injury in humans. Hepatology. 2019;70:346\u2013357","journal-title":"Hepatology"},{"key":"10633_CR179","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2147\/JIR.S299892","volume":"14","author":"C Tu","year":"2021","unstructured":"Tu C, Niu M, Wei A-W, et al. Susceptibility-related cytokine panel for prediction of polygonum multiflorum-induced hepatotoxicity in humans. J Inflamm Res. 2021;14:645\u2013655","journal-title":"J Inflamm Res"},{"key":"10633_CR180","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00204-019-02595-3","volume":"94","author":"L Zhang","year":"2020","unstructured":"Zhang L, Niu M, Wei A-W, et al. Risk profiling using metabolomic characteristics for susceptible individuals of drug-induced liver injury caused by polygonum multiflorum. Arch Toxicol. 2020;94:245\u2013256","journal-title":"Arch Toxicol"},{"key":"10633_CR181","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/cpt.1571","volume":"107","author":"SE Roth","year":"2020","unstructured":"Roth SE, Avigan MI, Bourdet D, et al. Next-generation DILI biomarkers: prioritization of biomarkers for qualification and best practices for biospecimen collection in drug development. Clin Pharmacol Ther. 2020;107:333\u2013346","journal-title":"Clin Pharmacol Ther"},{"key":"10633_CR182","unstructured":"US Department of Health and Human Services FDA, Center for Drug Evaluation and Research. Letter of Support for Drug-Induced Liver Injury (DILI) Biomarker(s). 2016. https:\/\/fda.report\/media\/99532\/Letter-of-Support-for-Drug-Induced-Liver-Injury-%28DILI%29-Biomarker%28s%29-7-25-16.pdf."},{"key":"10633_CR183","unstructured":"U.S. Department of Health and Human Services FDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. 2009. https:\/\/www.fda.gov\/media\/116737\/download."},{"key":"10633_CR184","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMra052270","volume":"354","author":"VJ Navarro","year":"2006","unstructured":"Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354:731\u2013739","journal-title":"N Engl J Med"},{"key":"10633_CR185","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1053\/j.gastro.2009.06.006","volume":"137","author":"WM Lee","year":"2009","unstructured":"Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137:3","journal-title":"Gastroenterology"},{"key":"10633_CR186","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1002\/hep.26001","volume":"57","author":"RH Squires","year":"2013","unstructured":"Squires RH, Dhawan A, Alonso E, et al. Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial. Hepatology. 2013;57:1542\u20131549","journal-title":"Hepatology"},{"key":"10633_CR187","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/1751-2980.12383","volume":"17","author":"PF Hu","year":"2016","unstructured":"Hu PF, Wang PQ, Chen H, et al. Beneficial effect of corticosteroids for patients with severe drug-induced liver injury. J Dig Dis. 2016;17:618\u2013627","journal-title":"J Dig Dis"},{"key":"10633_CR188","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000000319","volume":"7","author":"S Sundaram","year":"2020","unstructured":"Sundaram S, Vuppalanchi R, Saxena R, Chalasani N. Treatment of idiosyncratic drug-induced liver injury using steroids. ACG Case Rep J. 2020;7: e00319","journal-title":"ACG Case Rep J"},{"key":"10633_CR189","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000322298","volume":"84","author":"A Wree","year":"2011","unstructured":"Wree A, Dech\u00eane A, Herzer K, et al. Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury. Digestion. 2011;84:54\u201359","journal-title":"Digestion"},{"key":"10633_CR190","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/apt.16902","volume":"55","author":"J-B Wang","year":"2022","unstructured":"Wang J-B, Huang A, Wang Y, et al. Corticosteroid plus glycyrrhizin therapy for chronic drug- or herb-induced liver injury achieves biochemical and histological improvements: a randomised open-label trial. Aliment Pharmacol Ther. 2022;55:1297\u20131310","journal-title":"Aliment Pharmacol Ther"},{"key":"10633_CR191","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/apt.17373","volume":"57","author":"H Niu","year":"2023","unstructured":"Niu H, Ma J, Medina-Caliz I, et al. Potential benefit and lack of serious risk from corticosteroids in drug-induced liver injury: an international, multicentre, propensity score-matched analysis. Aliment Pharmacol Ther. 2023;57:886\u2013896","journal-title":"Aliment Pharmacol Ther"},{"key":"10633_CR192","doi-asserted-by":"publisher","first-page":"S-1304","DOI":"10.1016\/S0016-5085(20)33922-6","volume":"158","author":"J Ma","year":"2020","unstructured":"Ma J, Gu J, Lammert C. Characterization of steroid therapy for drug-induced liver injury. Gastroenterology. 2020;158:S-1304","journal-title":"Gastroenterology"},{"key":"10633_CR193","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015886","volume":"98","author":"Y-M Wan","year":"2019","unstructured":"Wan Y-M, Wu J-F, Li Y-H, Wu H-M, Wu X-N, Xu Y. Prednisone is not beneficial for the treatment of severe drug-induced liver injury: an observational study (STROBE compliant). Medicine (Baltimore). 2019;98: e15886","journal-title":"Medicine (Baltimore)"},{"key":"10633_CR194","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1111\/liv.14204","volume":"39","author":"Y Wang","year":"2019","unstructured":"Wang Y, Wang Z, Gao M, et al. Efficacy and safety of magnesium isoglycyrrhizinate injection in patients with acute drug-induced liver injury: a phase II trial. Liver Int. 2019;39:2102\u20132111","journal-title":"Liver Int"},{"key":"10633_CR195","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/liv.15290","volume":"42","author":"J Tang","year":"2022","unstructured":"Tang J, Gu J, Chu N, et al. Efficacy and safety of bicyclol for treating patients with idiosyncratic acute drug-induced liver injury: a multicenter, randomized, phase II trial. Liver Int. 2022;42:1803\u20131813","journal-title":"Liver Int"},{"key":"10633_CR196","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105404","volume":"164","author":"H Niu","year":"2021","unstructured":"Niu H, Sanabria-Cabrera J, Alvarez-Alvarez I, et al. Prevention and management of idiosyncratic drug-induced liver injury: systematic review and meta-analysis of randomised clinical trials. Pharmacol Res. 2021;164: 105404","journal-title":"Pharmacol Res"},{"key":"10633_CR197","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s11096-022-01402-x","volume":"44","author":"L Yao","year":"2022","unstructured":"Yao L, Zhang J, Jin J, et al. An analysis of the efficacy and safety of compound glycyrrhizin injections in the treatment of drug-induced liver injury using a nationwide database. Int J Clin Pharm. 2022;44:731\u2013740","journal-title":"Int J Clin Pharm"},{"key":"10633_CR198","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1111\/bcp.15575","volume":"89","author":"B Zhang","year":"2023","unstructured":"Zhang B, Jiang G, Wang L, et al. An analysis of silybin meglumine tablets in the treatment of drug-induced liver injury as assessed for causality with the updated Roussel Uclaf Causality Assessment Method using a nationwide database. Br J Clin Pharmacol. 2023;89:1329\u20131337","journal-title":"Br J Clin Pharmacol"},{"key":"10633_CR199","doi-asserted-by":"publisher","first-page":"300060521103981","DOI":"10.1177\/03000605211039810","volume":"49","author":"X Lei","year":"2021","unstructured":"Lei X, Zhang J, Xu Q, et al. Exploring the efficacy and safety of polyene phosphatidylcholine for treatment of drug-induced liver injury using the Roussel Uclaf causality assessment method: a propensity score matching comparison. J Int Med Res. 2021;49:3000605211039810","journal-title":"J Int Med Res"},{"key":"10633_CR200","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1080\/17512433.2021.1981859","volume":"14","author":"J Li","year":"2021","unstructured":"Li J, Zhang J, Xu X, et al. Hugan tablets for the treatment of RUCAM based drug-induced liver injury: a propensity score matching analysis using a nationwide database. Expert Rev Clin Pharmacol. 2021;14:1543\u20131550","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10633_CR201","first-page":"122","volume":"22","author":"W Liu","year":"2012","unstructured":"Liu W, Chen Z, Chen J. Efficacy of liver protection of Wuling Pills in outpatient anti-tuberculosis treatment: an observational study. Zhong Xi Yi Jie He Gan Bing Za Zhi. 2012;22:122\u2013123","journal-title":"Zhong Xi Yi Jie He Gan Bing Za Zhi"},{"key":"10633_CR202","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1177\/0300060514527058","volume":"42","author":"X Li","year":"2014","unstructured":"Li X, Zhou J, Chen S, et al. Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancer. J Int Med Res. 2014;42:906\u2013914","journal-title":"J Int Med Res"},{"key":"10633_CR203","doi-asserted-by":"publisher","first-page":"475","DOI":"10.5588\/ijtld.14.0579","volume":"19","author":"NH Chu","year":"2015","unstructured":"Chu NH, Li L, Zhang X, et al. Role of bicyclol in preventing drug-induced liver injury in tuberculosis patients with liver disease. Int J Tuberc Lung Dis. 2015;19:475\u2013480","journal-title":"Int J Tuberc Lung Dis"},{"key":"10633_CR204","first-page":"204","volume":"23","author":"Y Yan","year":"2015","unstructured":"Yan Y, Mo Y, Zhang D. Magnesium isoglycyrrhizinate prevention of chemotherapy-induced liver damage during initial treatment of patients with gastrointestinal tumors. (Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi) Chin J Hepatol. 2015;23:204\u2013208","journal-title":"(Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi) Chin J Hepatol"},{"key":"10633_CR205","first-page":"787","volume":"48","author":"G Li","year":"2019","unstructured":"Li G, Chen R, Wang W. A multicenter study of magnesium isoglycyrrhizinate injection to prevent liver injury induced by chemotherapy in hematological malignancies. Shaan Xi Yi Xue Za Zhi. 2019;48:787\u2013790","journal-title":"Shaan Xi Yi Xue Za Zhi"},{"key":"10633_CR206","unstructured":"Wu Y, Zhang J, Yang Y. Systematic review of efficacy and safety of magnesium lsoglycyrrhizinate in the prevention of liver injury induced by chemotherapy. Zhong Guo Yi Yuan Yong Yao Ping Jia Yu Fen Xi 2021;21:333\u20137"},{"key":"10633_CR207","first-page":"97","volume":"22","author":"S Qin","year":"2017","unstructured":"Qin S, Yang L, Wang K, et al. Efficacy and safety of magnesium isoglycyrrhizinate injection to prevent chemotherapy-induced acute liver injury (MAGIC-301): a multicenter, randomized, controlled clinical study. Lin Chuang Zhong Liu Xue Za Zhi. 2017;22:97\u2013106","journal-title":"Lin Chuang Zhong Liu Xue Za Zhi"},{"key":"10633_CR208","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1515\/med-2018-0010","volume":"13","author":"Y Chen","year":"2018","unstructured":"Chen Y, Ye P, Ren C, et al. Pharmacoeconomics of three therapeutic schemes for anti-tuberculosis therapy induced liver injury in China. Open Med (Wars). 2018;13:53\u201363","journal-title":"Open Med (Wars)"},{"key":"10633_CR209","first-page":"42","volume":"12","author":"N Leng","year":"2022","unstructured":"Leng N, Liu Y, Qiu Y, et al. Network meta-analysis of five liver protective drugs in the treatment of drug-induced liver injury. Zhong Guo Yi Yao Ke Xue. 2022;12:42\u201347","journal-title":"Zhong Guo Yi Yao Ke Xue"},{"key":"10633_CR210","first-page":"4321","volume":"24","author":"T Li","year":"2013","unstructured":"Li T, Chen R, Li J-R, Song Q-Y, Wu B. Economic evaluation of protecting liver and lowering transaminase regimens for chronic hepatitis B with elevated ALT. Zhong Guo Yao Fang. 2013;24:4321\u20134324","journal-title":"Zhong Guo Yao Fang"},{"key":"10633_CR211","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1002\/hep.23937","volume":"52","author":"A Reuben","year":"2010","unstructured":"Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a US multicenter, prospective study. Hepatology. 2010;52:2065\u20132076","journal-title":"Hepatology"},{"key":"10633_CR212","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S0140-6736(19)31894-X","volume":"394","author":"RT Stravitz","year":"2019","unstructured":"Stravitz RT, Lee WM. Acute liver failure. Lancet. 2019;394:869\u2013881","journal-title":"Lancet"},{"key":"10633_CR213","first-page":"CD012410","volume":"5","author":"ET Goh","year":"2018","unstructured":"Goh ET, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY. l-Ornithine l-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2018;5:CD012410","journal-title":"Cochrane Database Syst Rev"},{"key":"10633_CR214","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/j.1478-3231.2010.02213.x","volume":"30","author":"M Schmid","year":"2010","unstructured":"Schmid M, Peck-Radosavljevic M, K\u00f6nig F, Mittermaier C, Gangl A, Ferenci P. A double-blind, randomized, placebo-controlled trial of intravenous l-ornithine-l-aspartate on postural control in patients with cirrhosis. Liver Int. 2010;30:574\u2013582","journal-title":"Liver Int"},{"key":"10633_CR215","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/hep.32255","volume":"75","author":"A Jain","year":"2022","unstructured":"Jain A, Sharma BC, Mahajan B, et al. l-Ornithine l-aspartate in acute treatment of severe hepatic encephalopathy: a double-blind randomized controlled trial. Hepatology. 2022;75:1194\u20131203","journal-title":"Hepatology"},{"key":"10633_CR216","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/hep.29410","volume":"67","author":"SS Sidhu","year":"2018","unstructured":"Sidhu SS, Sharma BC, Goyal O, Kishore H, Kaur N. l-Ornithine l-aspartate in bouts of overt hepatic encephalopathy. Hepatology. 2018;67:700\u2013710","journal-title":"Hepatology"},{"key":"10633_CR217","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1053\/j.gastro.2009.02.050","volume":"136","author":"SK Acharya","year":"2009","unstructured":"Acharya SK, Bhatia V, Sreenivas V, Khanal S, Panda SK. Efficacy of l-ornithine l-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology. 2009;136:2159\u20132168","journal-title":"Gastroenterology"},{"key":"10633_CR218","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jhep.2015.08.018","volume":"64","author":"FS Larsen","year":"2016","unstructured":"Larsen FS, Schmidt LE, Bernsmeier C, et al. High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J Hepatol. 2016;64:69\u201378","journal-title":"J Hepatol"},{"key":"10633_CR219","doi-asserted-by":"publisher","first-page":"D1200","DOI":"10.1093\/nar\/gkab880","volume":"50","author":"G Xiong","year":"2022","unstructured":"Xiong G, Yang Z, Yi J, et al. DDInter: an online drug-drug interaction database towards improving clinical decision-making and patient safety. Nucleic Acids Res. 2022;50:D1200\u2013D1207","journal-title":"Nucleic Acids Res"},{"key":"10633_CR220","doi-asserted-by":"publisher","first-page":"S363","DOI":"10.1093\/cid\/ciaa1536","volume":"71","author":"N He","year":"2020","unstructured":"He N, Su S, Ye Z, et al. Evidence-based guideline for therapeutic drug monitoring of vancomycin: 2020 update by the division of therapeutic drug monitoring. Chin Pharmacol Soc Clin Infect Dis. 2020;71:S363\u2013S371","journal-title":"Chin Pharmacol Soc Clin Infect Dis"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10633-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-023-10633-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10633-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T19:12:41Z","timestamp":1712949161000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-023-10633-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,24]]},"references-count":220,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10633"],"URL":"https:\/\/doi.org\/10.1007\/s12072-023-10633-7","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,24]]},"assertion":[{"value":"7 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yimin Mao, Shiwu Ma, Chenghai Liu, Xiaoyan Liu, Minghua Su, Dongliang Li, Yiling Li, Gongying Chen, Jun Chen, Jinjun Chen, Jingmin Zhao, Xiaoyan Guo, Jieting Tang, Yuzheng Zhuge, Qing Xie, Wen Xie, Rongtao Lai, Dachuan Cai, Qingxian Cai, Yang Zhi and Xiaoyun Li have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or animal subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent in studies with human subjects and animal studies"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}